Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Availability More Than Strategy Driving Takeda's Shire Interest?

Executive Summary

While Takeda has admitted it is considering a possible offer for Shire, any deal would seem to go against some of the past strategy signals from the Japanese company, suggesting the availability of an increasingly rare acquisition target may be more of a key consideration.

Advertisement

Related Content

Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda's Deal Flurry Set To Wane
Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100654

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel